Hal Barron, GSK R&D chief, at Endpoints News' UKBIO 2019
December 17, 2020 04:08 PM ESTUpdated 04:25 PM
R&D
Coronavirus

Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

Kyle Blankenship

In the hunt for an ef­fec­tive Covid-19 ther­a­py, mon­o­clon­al an­ti­bod­ies have turned up mixed da­ta so far. Eli Lil­ly was Ex­hib­it A in Oc­to­ber when …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times